Modulation of glucagon receptor expression

Details Modulation of glucagon receptor expression Modulation of glucagon receptor expression

2011-04-05

2011-04-05

Chong, Kimberly (Department: 1635)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C536S024500, C536S024310, C536S024100

Reexamination Certificate

active

07919476

ABSTRACT:
Compounds, compositions and methods are provided for modulating the expression of glucagon receptor. The compositions comprise oligonucleotides, targeted to nucleic acid encoding glucagon receptor. Methods of using these compounds for modulation of glucagon receptor expression and for diagnosis and treatment of disease associated with expression of glucagon receptor are provided.

REFERENCES:
patent: 5492810 (1996-02-01), Caetano-Annoles et al.
patent: 5563036 (1996-10-01), Peterson et al.
patent: 5652222 (1997-07-01), Calabretta et al.
patent: 5693463 (1997-12-01), Edwards et al.
patent: 5708158 (1998-01-01), Hoey
patent: 5716780 (1998-02-01), Edwards et al.
patent: 5734039 (1998-03-01), Calabretta et al.
patent: 5770445 (1998-06-01), Kindsvogel et al.
patent: 5776725 (1998-07-01), Kindsvogel et al.
patent: 5801154 (1998-09-01), Baracchini et al.
patent: 5804383 (1998-09-01), Gruenert et al.
patent: 5919635 (1999-07-01), Kindsvogel et al.
patent: 5998148 (1999-12-01), Bennett et al.
patent: 6251873 (2001-06-01), Furusako et al.
patent: 6284538 (2001-09-01), Monia et al.
patent: 6455689 (2002-09-01), Schlingensiepen et al.
patent: 6492152 (2002-12-01), Canfield et al.
patent: 6582908 (2003-06-01), Fodor et al.
patent: 6677153 (2004-01-01), Iversen
patent: 6770486 (2004-08-01), Griffey et al.
patent: 6909031 (2005-06-01), Allen et al.
patent: 2001/0053519 (2001-12-01), Fodor et al.
patent: 2003/0087856 (2003-05-01), Bennett et al.
patent: 2003/0144242 (2003-07-01), Ward et al.
patent: 2003/0228597 (2003-12-01), Cowsert et al.
patent: 2004/0016030 (2004-01-01), Lowe et al.
patent: 2005/0014713 (2005-01-01), Freier et al.
patent: 2005/0074801 (2005-04-01), Monia et al.
patent: 2005/0142581 (2005-06-01), Griffey et al.
patent: 2006/0063730 (2006-03-01), Monia et al.
patent: 2007/0087987 (2007-04-01), Monia et al.
patent: WO 94/05789 (1994-03-01), None
patent: WO 99/13886 (1999-03-01), None
patent: WO 00/05418 (2000-03-01), None
patent: WO 01/92524 (2001-12-01), None
patent: WO 02/16553 (2002-02-01), None
patent: WO 02/45494 (2002-06-01), None
patent: WO 02/092772 (2002-11-01), None
patent: WO 03/010139 (2003-02-01), None
patent: WO 03/011887 (2003-02-01), None
patent: WO 2004/096016 (2004-11-01), None
patent: WO 2004/096996 (2004-11-01), None
patent: WO 2005/023995 (2005-03-01), None
patent: WO 2006/034348 (2006-03-01), None
patent: WO 2007/035771 (2007-03-01), None
Agrawal, S. et al., “Antisense therapeutics: is it as simple as complementary base recognition?”Mol. Med. Today(2000) 6:72-81.
Chambers, S. M. et al., “Glucagon receptor gene mutation in essential hypertension,”Nature Genetics(1996) 12:122.
Crooke, S. T., “Progress in Antisense Technology,”Annu. Rev. Med. (2004) 55:61-95.
Database Genseq (online) Jan. 7, 2002, “Human Stat3 Amplifying RT-PCR Primer #2,” Ref. WPI; 2002-034368/04. XP-002404609, Database accession No. AAD24334.
Database Genseq (online) Jan. 21, 1998, “Nucleotide Sequence of the RT-PCR Primer A,” Ref. WPI; 1998-531578/45. XP-002404610, Database accession No. AAV60964.
Database Genseq (online) Jan. 16, 2004, “Novel Mutant Protein Tyrosine Kinase-Related Oligonucleotide SeqID985,” Ref. WPI; 2004-718702/70. XP-002404611, Database accession No. ADT00997.
Database Genseq (online) Jan. 27, 2005, “Knock-Down Target Sequence #7049,” Ref. WPI; 2004-775940/76. XP-002404612, Database accession No. ADU41870.
Database Genseq (online) Jan. 27, 1999, “Oligonucleotide Derived From Pinene Synthase,” Ref. WPI; 1999-120496/10, XP-002404613, Database accession No. AAX08680.
Database Genseq (online) Jan. 5, 2002, “Human Polymorphism Associated DNA Sequence #415,” Ref. WPI; 2002-619265/66. XP-002404614, Database accession No. ABS60778.
Database Genseq (online) Jan. 30, 2000, “Hepatitis GB Virus PCR Primer SEQ ID No. 648,” Ref. WPI; 2000-338307/29. XP-002404615, Database accession No. AAA55422.
Database Genseq (online) Jan. 3, 1994, “Human Glucagon Receptor Primer ZC5432,” Ref. WPI: 1994-101194/12. XP-002404616, Database accession No. AAQ58770.
Database Genseq (online) Jan. 20, 2002, “Human KTOM1a Portion (ABQ63232) Probe #137,” Ref. WPI; 2002-479509/51. XP-002404617, Database accession No. ABQ63424.
Database Genseq (online) Jan. 20, 2002, “Oligonucleotide SEQ ID No. 21800 for Detecting SNP TSC0004359,” Ref. WPI: 2001-657177/75. XP-002404618, Database accession No. ABC21783.
Database Genseq (online) Jan. 20, 2002, “DNA Oligonucleotide Sequence #5,” Ref. WPI; 2002-088875/12. XP-002404712, Database accession No. ABA92515.
Database EM-PAT, Oct. 6, 1999. XP-02404619, retrieved from EBI. Database accession No. AR065230, abstract.
Database EM-PAT, Aug. 12, 2002, “Sequence 913 from patent WO0224750.” XP-002404620, Database accession No. AX475692.
Database Genseq (online) Jan. 25, 2001, “Human IL4 Gene PCR Primer SEQ ID No. 78,” Ref. WPI; 2001-316132/33. XP-002404621, Database accession No. AAH18819.
Fujisawa, T. et al., “A mutation in the glucagon receptor gene (Gly40Ser): heterogeneity in the association with diabetes mellitus,”Diabetologia(1995) 38:983-985.
Jen, K.-Y. et al., “Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies,”Stem Cells(2000) 18:307-319.
Liang, Y. et al., “Reduce Glucocorticoid Receptor Expression in Liver Ameliorates Diabetic Syndrome in ob/ob and db/db Mice,”ADA(2003) p. A134. Article 566-P.
Liang, Y. et al., “Reduction in Glucagon Receptor Expression by an Antisense Oligonucleotide Ameliorates Diabetic Syndrome indb/dbMice,”Diabetes(2004) 53:410-417.
Link, J. T., “Pharmacological regulation of hepatic glucose production,”Curr. Opin. Invest. Drugs(2003) 4(4):421-429.
Lok, S. et al., “The human glucagon receptor encoding gene: structure. cDNA sequence and chromosomal localization,”Gene(1994) 140:203-209.
MacNeil, D. J. et al., “Cloning and Expression of a Human Glucagon Receptor,”Biochem. Biophys. Res. Commun. (1994) 198(1):328-334.
Madsen, P. et al., “Advances in Non-Peptide Glucagon Receptor Antagonists,”Curr. Pharm. Design(1995) 5:683-691.
Opalinska, J. B. et al., “Nucleic-Acid Therapeutics: Basic Principles and Recent Applications,”Nature Reviews Drug Discovery(2002) 1:503-514.
Siani, A. et al., “Gly40Ser Polymorphism of the Glucagon Receptor Gene Is Associated with Central Adiposity in Men,”Obes. Res. (2001) 9:722-726.
Taylor, M. F. et al., “Antisense oligonucleotides: a systematic high-throughput approach to target validation and gene function determination,”DDT(1999) 4(12):562-567.
Branch et al., “A good antisense molecule is hard to find,” TIBS (1998) 23:45-50.
Chin “On the Preparation and Utilization of Isolated and Purified Oligonucleotides” Document purportedly located on a CD-ROM and contributed to the public collection of the Katherine R. Everett Law Library of the University of North Carolina on Mar. 14, 2002.
Crooke et al., “Basic Principles of Antisense Therapeutics” Antisense Research and Application (1998) Chapter 1:1-50.
New England Biolabs 1998/99 Catalog (cover page and pp. 121 and 284).
Reynolds et al., “Rational siRNA design for RNA interference” Nature Biotechnology (2004) 22(3):326-330.
Sanghvi et al., “Heterocyclic Base Modifications in Nucleic Acids and Their Applications in Antisense Oligonucleotides” Antisense Research and Applications (1993) pp. 273-288.
International Search Report for Application No. PCT/US04/12960 dated Aug. 30, 2006.
International Search Report for Application No. PCT/US04/13120 dated Jun. 27, 2005.
Office Action for U.S. Appl. No. 10/832,622 dated Mar. 8, 2006.
Office Action for U.S. Appl. No. 10/832,622 dated May 1, 2007.
Office Action for U.S. Appl. No. 10/832,622 dated Mar. 4, 2009.
Final Rejection for U.S. Appl

Affiliated with

Also associated with

Rating

Modulation of glucagon receptor expression does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Modulation of glucagon receptor expression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulation of glucagon receptor expression will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2633513